perifosine has been researched along with Cancer of Kidney in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samlowski, W; Vogelzang, NJ; Weissman, A | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC; Pietri, JE; Tepper, CG | 1 |
| Cho, DC; Figlin, RA; Flaherty, KT; Hutson, TE; Michaelson, MD; Puzanov, I; Richards, P; Samlowski, W; Somer, B; Sosman, JA; Sportelli, P; Vogelzang, NJ | 1 |
| Cho, DC; Srivastava, N | 1 |
1 review(s) available for perifosine and Cancer of Kidney
| Article | Year |
|---|---|
Perifosine in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Molecular Structure; Phosphorylcholine; Randomized Controlled Trials as Topic | 2013 |
1 trial(s) available for perifosine and Cancer of Kidney
| Article | Year |
|---|---|
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Phosphorylcholine; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Salvage Therapy; Survival Rate; Vascular Endothelial Growth Factor A | 2012 |
2 other study(ies) available for perifosine and Cancer of Kidney
| Article | Year |
|---|---|
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2009 |
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-8; Kidney Neoplasms; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases | 2012 |